New Indication: Tazemetostat for relapsed/refractory follicular lymphoma

New Indication: Tazemetostat for relapsed/refractory follicular lymphoma

Single-arm phase 2 trial
Relapsed or refractory to >=2 systemic therapies
EZH2 mutant (n=45) and EZH2 WT (n=54) categories
Results: EZH2 mutant and EZH2 WT
ORR: 69% (53-82%) and 35% (23-49%)
Median DoR: 10.9 mos (7.2 mos – not estimable) and 13.0 mos (5.6 mos – not estimable)
Grade >=3 adverse events: Thrombocytopenia (3%), neutropenia (3%), anemia (2%)

Lancet Oncology 2020 Oct 6. Online ahead of print.
Morschhauser F, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
https://doi.org/10.1016/S1470-2045(20)30

Reviewed by Ulas Darda Bayraktar, MD on Oct 16, 2020

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More